← All trials
NCT03532217
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2018
- Primary completion
- Oct 14, 2021
- Completion date
- Sep 14, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Washington University in St. LouisLead sponsor
- Bavarian NordicCollaborator
- Prostate Cancer FoundationCollaborator
- Washington University in St. LouisCollaborator
- Washington University in St. LouisOverall official - principal investigator
- Washington University in St. LouisOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.